Bian Chaorong, Zhou Peng, Shen Ping, Zang Yunpeng, Liu Wen
The First Clinical Medical College of Xuzhou Medical University，Xuzhou，221000，China.
TheOtolaryngology Department of the Affiliated Hospital of Xuzhou Medical University.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025 Jan;39(1):66-70;76. doi: 10.13201/j.issn.2096-7993.2025.01.014.
To explore the efficacy of vonoprazan fumarate in the treatment of laryngopharyngeal reflux disease（LPRD） evaluated by the Chinese version of the RSS-12 scale. A total of 100 LPRD patients treated in the otolaryngology-head and neck surgery outpatient clinic of our hospital were randomly divided into two groups（50 cases each）. The observation group was treated with vonoprazan fumarate（20 mg, once daily）, and the control group was treated with esomeprazole enteric-coated capsules（20 mg, twice daily） for 12 weeks. The selected observation indicators in this study included RSI, the Chinese version of RSS-12, and RFS scores before and after treatment. Prior to treatment, there was no statistically significant difference in the Chinese version of RSS-12, RSI, and RFS between the two groups（>0.05）. After 8 and 12 weeks of antacid treatment, both the Chinese version of RSS-12 and RSI significantly decreased in both group （<0.05）. The changes in symptoms were particularly noticeable between 0-8 weeks of treatment according to the Chinese version of RSS-12 and RSI. After 12 weeks of treatment, the RFS scores significantly decreased compared to pretreatment levels （<0.05）. After 12 weeks of antacid treatment, according to the Chinese version of RSS-12, 80% of patients in the observation group showed a good therapeutic response, compared to 64% in the control group; according to RSI, 90% of patients in the observation group showed a good therapeutic response, compared to 84% in the control group. There was no statistically significant difference in the treatment effect between the two groups after 12 weeks of treatment（>0.05）. Vonoprazan fumarate can significantly improve the symptoms and signs of laryngopharyngeal reflux, and their treatment effect is not inferior to proton pump inhibitors. Compared with RSI, the Chinese version of RSS-12 can serve as a new screening tool for clinical diagnosis of LPRD in China.
探讨富马酸沃克（伏诺拉生）治疗喉咽反流病（LPRD）的疗效，采用中文版RSS-12量表进行评估。选取我院耳鼻咽喉头颈外科门诊收治的100例LPRD患者，随机分为两组（每组50例）。观察组采用富马酸沃克（20mg，每日1次）治疗，对照组采用埃索美拉唑肠溶胶囊（20mg，每日2次）治疗，疗程12周。本研究选取的观察指标包括治疗前后的反流症状指数（RSI）、中文版RSS-12量表及反流因子评分（RFS）。治疗前，两组患者中文版RSS-12量表、RSI及RFS差异均无统计学意义（P>0.05）。抑酸治疗8周和12周后，两组患者中文版RSS-12量表及RSI均显著下降（P<0.05）。根据中文版RSS-12量表及RSI，治疗0-8周症状变化尤为明显。治疗12周后，RFS评分较治疗前显著下降（P<0.05）。抑酸治疗12周后，根据中文版RSS-量表，观察组80%的患者显示出良好的治疗反应，对照组为64%；根据RSI，观察组90%的患者显示出良好的治疗反应，对照组为84%。治疗12周后两组治疗效果差异无统计学意义（P>0.05）。富马酸沃克能显著改善喉咽反流的症状和体征，其治疗效果不劣于质子泵抑制剂。与RSI相比，中文版RSS-12量表可作为我国临床诊断LPRD的新型筛查工具。
